Early-Stage Colon Cancer: Making Informed Decisions – Live Web Chat withMark Kozloff, MD
Dr. Mark Kozloff is a Clinical Associate of Medicine in the Center for Gastrointestinal Oncology at the University of Chicago. Click here for Dr. Kozloff’s bio.
Each year in the United States, more than 100,000 people are diagnosed with colon cancer. Advances in early detection and treatment have made important contributions to improved survival, but researchers continue to explore more targeted and more individualized approaches to cancer care.
As cancer research has evolved, it has become apparent that no two cancers are exactly alike. Even among people with the same type and stage of cancer, the specific characteristics of the cancer can vary greatly. These differences can have a profound effect on prognosis and response to treatment. The good news is that a growing collection of tests are available to describe the important characteristics of a tumor and guide treatment choices.
On Monday, December 10, 2012 at 6:00 PM Dr. Mark Kozloff discussed treatment options available for early-stage colon cancer. Dr. Kozloff specializes in the treatment of colorectal cancer and has published widely on the efficacy, safety and effects of drug therapies for cancer. The archive of this Web Chat will be available on 12/13.
This program is sponsored by Genomic Health, Inc. Please visit Oncotype DX to learn more.
The Live Web Chat is not intended to be a substitute for healthcare professional medical advice, diagnosis, or treatment. Speak to your healthcare provider about any questions you may have regarding your health.
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey?
- Sign up for monthly newsletters on colon cancer here.
- Get the facts about colon cancer here.
- Join ongoing discussions with other individuals affected by colon cancer in the CancerConnect private online colon cancer community here.
Copyright © 2018 CancerConnect. All Rights Reserved.